Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the publication in the on-line edition of the journal PLoS ONE (www.plosone.org) of results demonstrating that ganetespib, a potent second generation inhibitor of heat shock protein 90 (Hsp90), exhibits potent in vitro and in vivo activity in a range of solid and hematologic tumor cells that are dependent on Janus-associated kinase 2 (JAK2) activity for growth and survival.
